Wingate Wealth Advisors Inc. Acquires New Holdings in Johnson & Johnson (NYSE:JNJ)

Wingate Wealth Advisors Inc. bought a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 1,612 shares of the company's stock, valued at approximately $233,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Powers Advisory Group LLC boosted its stake in Johnson & Johnson by 0.6% during the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company's stock worth $1,538,000 after acquiring an additional 61 shares in the last quarter. Knuff & Co LLC boosted its stake in Johnson & Johnson by 0.7% during the third quarter. Knuff & Co LLC now owns 9,466 shares of the company's stock worth $1,534,000 after acquiring an additional 64 shares in the last quarter. Vertex Planning Partners LLC boosted its stake in Johnson & Johnson by 1.3% during the third quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company's stock worth $844,000 after acquiring an additional 65 shares in the last quarter. Freedom Day Solutions LLC boosted its stake in Johnson & Johnson by 1.1% during the third quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company's stock worth $1,016,000 after acquiring an additional 66 shares in the last quarter. Finally, Traphagen Investment Advisors LLC boosted its stake in Johnson & Johnson by 0.6% during the third quarter. Traphagen Investment Advisors LLC now owns 10,483 shares of the company's stock worth $1,699,000 after acquiring an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Guggenheim increased their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a "neutral" rating in a research note on Monday, February 3rd. Barclays raised their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 28th. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 23rd. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Finally, Bank of America dropped their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $170.67.

Johnson & Johnson Stock Performance

NYSE JNJ traded down $1.05 during trading hours on Friday, reaching $156.20. 6,402,249 shares of the company were exchanged, compared to its average volume of 9,304,454. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The business's 50 day simple moving average is $147.87 and its 200-day simple moving average is $155.96. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $376.08 billion, a P/E ratio of 23.49, a P/E/G ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter last year, the company posted $2.29 earnings per share. The firm's quarterly revenue was up 5.3% compared to the same quarter last year. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.18%. Johnson & Johnson's payout ratio is 74.59%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company's stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.